Akshay K. Vaishnaw's most recent trade in Scholar Rock Holding Corp was a trade of 5,130 Common Stock done at an average price of $29.6 . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director, President of R&D | Sale of securities on an exchange or to another person at price $ 29.63 per share. | 29 May 2025 | 5,130 | 617,825 (2%) | 0% | 29.6 | 152,000 | Common Stock |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director, President of R&D | Sale of securities on an exchange or to another person at price $ 30.01 per share. | 29 May 2025 | 1,620 | 616,205 (2%) | 0% | 30.0 | 48,612 | Common Stock |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2025 | 110,067 | 110,067 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 500,000 | 622,955 (2%) | 1% | 0 | Common Stock | |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 100,000 | 122,955 (0%) | 0% | 0 | Common Stock | |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 22,955 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2023 | 5,082 | 22,972 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2023 | 3,859 | 26,831 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2023 | 1,869 | 24,191 (0%) | 0% | 185.5 | 346,774 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2023 | 1,107 | 23,084 (0%) | 0% | 186.4 | 206,334 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2023 | 771 | 26,060 (0%) | 0% | 184.7 | 142,404 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2023 | 192 | 22,774 (0%) | 0% | 189.3 | 36,348 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2023 | 101 | 22,983 (0%) | 0% | 187.4 | 18,924 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2023 | 17 | 22,966 (0%) | 0% | 188.4 | 3,203 | Common Stock | |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Editas Medicine Inc | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 26 Apr 2023 | 5,312 | 20,282 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 26 Apr 2023 | 1,013 | 18,162 (0%) | 0% | 194.9 | 197,474 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 26 Apr 2023 | 910 | 19,175 (0%) | 0% | 193.9 | 176,476 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 26 Apr 2023 | 197 | 20,085 (0%) | 0% | 193.2 | 38,056 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 26 Apr 2023 | 168 | 17,890 (0%) | 0% | 197.1 | 33,109 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 26 Apr 2023 | 104 | 18,058 (0%) | 0% | 195.7 | 20,348 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 27 Feb 2023 | 11,986 | 11,986 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 27 Feb 2023 | 5,790 | 5,790 | - | - | Restricted Stock Units | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 10 Feb 2023 | 30,913 | 53,014 (0%) | 0% | 63 | 1,947,519 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 10 Feb 2023 | 30,913 | 0 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 10 Feb 2023 | 19,447 | 19,272 (0%) | 0% | 216.4 | 4,207,942 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 10 Feb 2023 | 10,279 | 38,719 (0%) | 0% | 215.6 | 2,216,050 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 10 Feb 2023 | 4,302 | 14,970 (0%) | 0% | 217.0 | 933,749 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 10 Feb 2023 | 2,307 | 48,998 (0%) | 0% | 214.3 | 494,344 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 10 Feb 2023 | 1,709 | 51,305 (0%) | 0% | 213.1 | 364,239 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 05 Dec 2022 | 2,368 | 0 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 05 Dec 2022 | 2,368 | 23,425 (0%) | 0% | 42.2 | 99,977 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 05 Dec 2022 | 1,587 | 30,913 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 05 Dec 2022 | 1,587 | 21,057 (0%) | 0% | 63 | 99,981 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 05 Dec 2022 | 1,324 | 22,101 (0%) | 0% | 226.2 | 299,489 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 05 Dec 2022 | 1,124 | 19,470 (0%) | 0% | 89.0 | 99,980 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 05 Dec 2022 | 1,124 | 28,876 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2022 | 5,479 | 18,919 (0%) | 0% | 189.8 | 1,039,695 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2022 | 5,083 | 16,298 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2022 | 4,241 | 20,539 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2022 | 3,859 | 24,398 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2022 | 198 | 18,346 (0%) | 0% | 210.8 | 41,729 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2022 | 195 | 18,724 (0%) | 0% | 210.2 | 40,993 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President | 03 Aug 2022 | 180 | 18,544 (0%) | 0% | 210.7 | 37,919 | Common Stock | |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Editas Medicine Inc | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 5,417 | 16,632 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 2,415 | 14,217 (0%) | 0% | 189.1 | 456,749 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 1,000 | 11,862 (0%) | 0% | 191.5 | 191,450 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 303 | 11,215 (0%) | 0% | 195.1 | 59,118 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 145 | 11,518 (0%) | 0% | 193.7 | 28,082 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 144 | 13,207 (0%) | 0% | 190.0 | 27,363 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 144 | 13,351 (0%) | 0% | 189.2 | 27,251 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 142 | 12,987 (0%) | 0% | 190.4 | 27,035 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 137 | 13,833 (0%) | 0% | 187.1 | 25,630 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 130 | 13,703 (0%) | 0% | 187.4 | 24,356 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 127 | 13,576 (0%) | 0% | 188.3 | 23,909 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 126 | 11,663 (0%) | 0% | 193.4 | 24,365 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 125 | 12,862 (0%) | 0% | 190.9 | 23,858 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 124 | 13,970 (0%) | 0% | 186.2 | 23,091 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 122 | 14,094 (0%) | 0% | 186.5 | 22,751 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 73 | 13,503 (0%) | 0% | 189.0 | 13,798 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 73 | 11,789 (0%) | 0% | 192.2 | 14,034 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 73 | 13,129 (0%) | 0% | 190.3 | 13,894 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 8 | 13,495 (0%) | 0% | 189.1 | 1,513 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 5 | 13,202 (0%) | 0% | 190.2 | 951 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 21 Dec 2021 | 1 | 14,216 (0%) | 0% | 191 | 191 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 09 Aug 2021 | 10,834 | 11,215 (0%) | 0% | 200 | 2,166,800 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 09 Aug 2021 | 10,834 | 10,832 | - | - | Performance Stock Option 2013 (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 09 Aug 2021 | 10,834 | 22,049 (0%) | 0% | 63 | 682,542 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 18 Jun 2021 | 14,708 | 11,215 (0%) | 0% | 175 | 2,573,900 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 18 Jun 2021 | 10,834 | 24,953 (0%) | 0% | 63 | 682,542 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 18 Jun 2021 | 10,834 | 21,666 | - | - | Performance Stock Option 2013 (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 18 Jun 2021 | 970 | 25,923 (0%) | 0% | 42.2 | 40,953 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 18 Jun 2021 | 970 | 2,368 | - | - | Stock Option (right to buy) | ||
| Editas Medicine Inc | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 11,538 | 11,538 | - | - | Stock Option (right to buy) | |
| Scholar Rock Holding Corp | Akshay K. Vaishnaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 5,083 | 22,908 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 2,266 | 16,936 (0%) | 0% | 131.8 | 298,546 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 1,892 | 14,756 (0%) | 0% | 136.8 | 258,901 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 1,678 | 21,230 (0%) | 0% | 136.8 | 229,483 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 989 | 20,241 (0%) | 0% | 137.6 | 136,086 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 622 | 19,619 (0%) | 0% | 138.6 | 86,234 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 530 | 14,226 (0%) | 0% | 137.6 | 72,928 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 417 | 19,202 (0%) | 0% | 140.0 | 58,388 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 203 | 16,648 (0%) | 0% | 135.4 | 27,488 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 107 | 14,119 (0%) | 0% | 138.5 | 14,817 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 19 Apr 2021 | 85 | 16,851 (0%) | 0% | 134.6 | 11,438 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 24 Feb 2021 | 28,800 | 28,800 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 11 Feb 2021 | 8,334 | 25,000 | - | - | Performance Stock Option 2017 (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 11 Feb 2021 | 5,416 | 19,535 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 11 Feb 2021 | 1,618 | 17,917 (0%) | 0% | 156 | 252,408 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 11 Feb 2021 | 92 | 17,825 (0%) | 0% | 152.5 | 14,033 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 29 Sep 2020 | 971 | 14,119 (0%) | 0% | 140 | 135,940 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 29 Sep 2020 | 971 | 3,338 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharmaceuticals Inc | Akshay K. Vaishnaw | President, R&D | 29 Sep 2020 | 971 | 15,090 (0%) | 0% | 42.2 | 40,996 | Common Stock |